The latest data point for Pfizer's Return on Sales (ROS) in Q4'25 shows a value of -0.09%, indicating a quarterly loss in profitability relative to sales. This marks a downturn from the positive figures observed in the preceding three quarters of 2025. Over the period from Q1'23 to Q4'25, Pfizer's ROS has exhibited significant volatility, fluctuating between a high of 0.34% in Q1'23 and a low of -0.29% in Q4'23, with a general pattern of alternating positive and negative quarters. Notable declines occurred in Q3'23 and Q4'23, followed by a recovery in Q1'24 and Q3'24, but the metric remained unstable, dipping into negative territory in Q2'24 and Q4'25, suggesting ongoing challenges in maintaining consistent operational efficiency.